- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01703533
A Safety Study of NNZ-2566 in Patients With Rett Syndrome
A Phase II Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Escalation Study of NNZ-2566 in Rett Syndrome
Study Overview
Detailed Description
Rett Syndrome is a developmental disorder primarily if not exclusively affecting females. The disorder is characterized by apparent normal development in early infancy (6-18 months), followed by a period of regression with onset of systemic and neurological signs. The CNS symptoms of Rett Syndrome include learning disability, autism and epilepsy and these can be severe and highly debilitating. Affected individuals also show signs of autonomic dysfunction, reflected in cardiovascular and respiratory abnormalities. There is no currently effective treatment for Rett Syndrome.
This study will investigate the safety and tolerability of treatment with oral administration of NNZ-2566 at 35 mg/kg or 70 mg/kg BID in adolescent or adult females with Rett Syndrome. The study also will also investigate measures of efficacy during treatment.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294-0113
- University of Alabama
-
-
Minnesota
-
Saint Paul, Minnesota, United States, 55101
- Gillette Children's Specialty Healthcare
-
-
Texas
-
Houston, Texas, United States, 77030
- Baylor School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of Rett Syndrome with proven mutation of the MeCP2 gene
- Age 16 to 45 years
- Severity rating of between 10 and 36 (Rett Syndrome Natural History/Clinical Severity Scale)
- Concomitant medications must be stable for >4 weeks prior to enrollment. The following concomitant medications are permitted: anticonvulsants which do not have liver inducing effects; beta-blockers; medications for the treatment of gastroesophageal reflux disease (GERD); medications for the treatment of chronic respiratory conditions such as asthma; medications for the treatment of anxiety, of depression and of psychosis, hormonal contraceptives. Melatonin for difficulties with sleep onset.
- Ability to swallow study medication provided as a liquid solution, or via gastrostomy tube
Exclusion Criteria:
- No detectable abnormality of the EEG during screening period
- Actively undergoing regression
- QTcF exclusions (any of the following): baseline/screening QT/QTcF interval of 450 msec; history of risk factors for torsade de pointes (e.g. heart failure, hypokalemia (serum potassium at screening < 3.0 mmol/L) or family history of long QT syndrome; QT/QTcF prolongation previously or currently controlled with medication
- Current treatment with insulin
- Hgb A1C values outside the normal reference range at screening
- Current or past treatment with IGF-1
- Current or past treatment with growth hormone
- Current treatment with N-methyl-D-aspartate (NMDA) antagonists
- Current or planned use of non-medication based interventional therapy during the period of the study (defined as 4-6 week screening period followed by 4 week dosing and 2 week follow-up period)
- Current clinically significant cardiovascular, renal, hepatic or respiratory disease
- Gastrointestinal disease which may interfere with the absorption, distribution, metabolism or excretion of the the study medication
- History of, or current cerebrovascular disease or brain trauma
- History of, or current significant endocrine disorder e.g. hypo or hyperthyroidism or diabetes mellitus
- History of, or current malignancy
- Clinically significant abnormalities in safety laboratory tests, vital signs or ECG, as measured at screening or baseline
- Confirmed pregnancy
- Significant hearing and/or visual impairment that may affect ability to complete the test procedures
- Enrollment in another clinical trial within the previous 30 days
- Previously randomized in this clinical trial
- Allergy to strawberries
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: NNZ-2566
Glycyl-L-2-Methylpropyl-L-Glutamic Acid
|
Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
|
Placebo Comparator: Placebo (strawberry flavored solution)
Strawberry flavored solution and Water for Injection
|
Strawberry flavored solution and Water for Injection
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: Through to Day 40
|
Incidence of adverse events (AE), including Serious adverse events (SAE), will be evaluated between the two NNZ-2566 doses and placebo.
SAEs will be examined from randomization through to Day 40.
AEs will be examined from dosing through to Day 40.
|
Through to Day 40
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in EEG activity
Time Frame: Baseline through to Day 40
|
Absolute change in the number of spikes in the EEG per hour during the awake state will be calculated for each subject between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40). Absolute change in the power of frequency bands in the EEG over an hour in the awake state as determined by the Fast Fourier method will be calculated for each subject between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40). Changes in the frequency of the characteristic repetitive stereotypic hand movements during wakefulness will be calculated for each subject between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40). |
Baseline through to Day 40
|
Behavior
Time Frame: Baseline through to Day 40
|
The following measures will be assessed at baseline and Day 26 and the changes compared between active and placebo groups: Symptom severity according to the Rett Syndrome Natural History Motor Behavior Assessment (MBA), Clinical Severity Scale (CSS), Aberrant Behavior Checklist (ABC), Vineland Adaptive Behavior Scale (VABS), and Clinical Global Impression of Severity (CGI-S). The following assessments will be undertaken at the additional time points specified: CGI-S (screening, baseline, Days 5, 14, 26, and 40), CGI-I (Days 5, 14, 26, and 40), MBA (Baseline, Days 26 and 40), CSS (screening, baseline, Days 26, and 40). |
Baseline through to Day 40
|
Physiological changes
Time Frame: Baseline through to Day 40
|
Changes in autonomic function, i.e. respiratory rhythm, hyperventilation, apneas, oxygen desaturation, and heart rate variation will be calculated between baseline (pre-treatment), during treatment (Days 1 thru 4, 14 and 26) and after treatment (Day 40).
|
Baseline through to Day 40
|
Global and Functional outcome Measures
Time Frame: Baseline through to Day 40
|
Global outcome as measured by the change in scores on the Rett Syndrome Clinical Severity Score (CSS), The Rett Syndrome Motor-Behavior Assessment Scale (MBA), and the Clinical Global Impression - Severity and Improvement scales (CGI-S and -I) from baseline, during treatment, and post treatment. Changes in caregiver assessment of the top three causes for concern as assessed via a Visual Analogue Scale (VAS) will be evaluated for each subject between baseline (pre-treatment), during treatment (Day 26) and after treatment (Day 40). Changes in the Aberrant Behavior Checklist (ABC) and Vineland Adaptive Behavior Scales (VABS) will be calculated for each subject between baseline (pre-treatment), and during treatment (Day 26). |
Baseline through to Day 40
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics
Time Frame: Baseline through to Day 40
|
The following pharmacokinetic measures will be calculated from NNZ-2566 concentrations in whole blood: Tmax, Cmax (peak), Cmin (trough), CAV at steady state, T1/2 and AUC.
|
Baseline through to Day 40
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Daniel G Glaze, M.D., Baylor College of Medicine
- Principal Investigator: Jeffrey L Neul, M.D., Ph.D., Baylor College of Medicine
- Principal Investigator: Alan Percy, MD, University of Alabama at Birmingham
- Principal Investigator: Timothy Feyma, MD, Gillette Children's Specialty Healthcare
- Principal Investigator: Arthur Beisang, MD, Gillette Children's Specialty Healthcare
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Neu-2566-RETT-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rett Syndrome
-
University of Alabama at BirminghamUniversity of Colorado, Denver; Eunice Kennedy Shriver National Institute of... and other collaboratorsCompletedRett Syndrome, Preserved Speech Variant | Mecp2 Duplication Syndrome | Rett-related DisordersUnited States
-
Children's Hospital of PhiladelphiaNational Institute of Neurological Disorders and Stroke (NINDS); Vanderbilt...RecruitingRett Syndrome | Rett Syndrome, Atypical | RTTUnited States
-
University of Alabama at BirminghamUniversity of Colorado, Denver; Eunice Kennedy Shriver National Institute of... and other collaboratorsCompletedRett Syndrome | MECP2 Duplication Disorder | Rett-related DisorderUnited States
-
International Rett Syndrome FoundationBaylor College of Medicine; Children's Hospital of Philadelphia; University of... and other collaboratorsRecruitingNervous System Diseases | Neurologic Manifestations | Neurobehavioral Manifestations | Genetic Diseases, X-Linked | Intellectual Disability | Neurodevelopmental Disorders | Neurologic Disorder | Rett Syndrome | Genetic Disease | Rett Syndrome, AtypicalUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University Hospital, Basel, SwitzerlandNovartisCompletedRett's SyndromeSwitzerland
-
ACADIA Pharmaceuticals Inc.CompletedRett SyndromeUnited States
-
ACADIA Pharmaceuticals Inc.Completed
-
IRCCS Eugenio MedeaAssociazione Italiana Rett (AIRett) O.n.l.u.s.Completed
-
Rett Syndrome Research TrustDuke UniversityCompletedRett SyndromeUnited States
Clinical Trials on NNZ-2566
-
Neuren Pharmaceuticals LimitedCompleted
-
Neuren Pharmaceuticals LimitedCompletedBrain Injuries, TraumaticAustralia
-
Neuren Pharmaceuticals Limitedrettsyndrome.orgCompleted
-
Neuren Pharmaceuticals LimitedTerminatedConcussionUnited States
-
Neuren Pharmaceuticals LimitedCompletedBrain InjuriesUnited States
-
Neuren Pharmaceuticals LimitedCompletedBrain InjuriesUnited States
-
Neuren Pharmaceuticals LimitedCompleted
-
Neuren Pharmaceuticals LimitedCompletedHealthy VolunteersAustralia
-
Neuren Pharmaceuticals LimitedRecruitingPitt Hopkins SyndromeUnited States
-
Neuren Pharmaceuticals LimitedRecruiting